← Klinické štúdie  •  Glomerulopatie

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

Nábor prebieha  •  Fáza 1  •  intervenčná  •  NCT06975787

Stručný súhrn

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).

The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.

This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Základné údaje

Základné údaje o štúdii
OchoreniaLupus Nephritis (LN)
Intervencie DRUG: Vonsetamig
DRUG: Odronextamab
SponzorRegeneron Pharmaceuticals
Plánovaný počet90
Začiatok2025-12-22
Predp. ukončenie (primárne)2029-09-09
KrajinyUnited States, France, Germany, South Korea, Spain, Taiwan
Posledná aktualizácia2026-06-17
Upozornenie: údaje sú orientačné a podliehajú zmenám. Úplné vstupné/vylučovacie kritériá, kontakty a aktuálny stav nájdete v oficiálnom registri. Tento prehľad nenahrádza lekársku konzultáciu.